Logo image of NVNO

ENVVENO MEDICAL CORP (NVNO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NVNO - US29415J1060 - Common Stock

0.336 USD
-0.02 (-6.67%)
Last: 1/12/2026, 8:17:05 PM
0.3475 USD
+0.01 (+3.42%)
After Hours: 1/12/2026, 8:17:05 PM
Fundamental Rating

2

Taking everything into account, NVNO scores 2 out of 10 in our fundamental rating. NVNO was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While NVNO has a great health rating, there are worries on its profitability. NVNO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year NVNO has reported negative net income.
In the past year NVNO has reported a negative cash flow from operations.
In the past 5 years NVNO always reported negative net income.
In the past 5 years NVNO always reported negative operating cash flow.
NVNO Yearly Net Income VS EBIT VS OCF VS FCFNVNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of NVNO (-67.89%) is worse than 71.89% of its industry peers.
Looking at the Return On Equity, with a value of -74.59%, NVNO is in line with its industry, outperforming 41.62% of the companies in the same industry.
Industry RankSector Rank
ROA -67.89%
ROE -74.59%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
NVNO Yearly ROA, ROE, ROICNVNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

NVNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVNO Yearly Profit, Operating, Gross MarginsNVNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NVNO has more shares outstanding
The number of shares outstanding for NVNO has been increased compared to 5 years ago.
There is no outstanding debt for NVNO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NVNO Yearly Shares OutstandingNVNO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
NVNO Yearly Total Debt VS Total AssetsNVNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -7.08, we must say that NVNO is in the distress zone and has some risk of bankruptcy.
NVNO has a Altman-Z score of -7.08. This is in the lower half of the industry: NVNO underperforms 74.59% of its industry peers.
NVNO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.08
ROIC/WACCN/A
WACCN/A
NVNO Yearly LT Debt VS Equity VS FCFNVNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 13.12 indicates that NVNO has no problem at all paying its short term obligations.
NVNO has a better Current ratio (13.12) than 96.76% of its industry peers.
NVNO has a Quick Ratio of 13.12. This indicates that NVNO is financially healthy and has no problem in meeting its short term obligations.
NVNO has a Quick ratio of 13.12. This is amongst the best in the industry. NVNO outperforms 97.84% of its industry peers.
Industry RankSector Rank
Current Ratio 13.12
Quick Ratio 13.12
NVNO Yearly Current Assets VS Current LiabilitesNVNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

1

3. Growth

3.1 Past

NVNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.80%, which is quite good.
EPS 1Y (TTM)18.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.86% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.26%
EPS Next 2Y9.4%
EPS Next 3Y12.02%
EPS Next 5Y12.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVNO Yearly Revenue VS EstimatesNVNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2026 2027 2028 5M 10M 15M 20M 25M
NVNO Yearly EPS VS EstimatesNVNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8 -10

0

4. Valuation

4.1 Price/Earnings Ratio

NVNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVNO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVNO Price Earnings VS Forward Price EarningsNVNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVNO Per share dataNVNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as NVNO's earnings are expected to grow with 12.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.4%
EPS Next 3Y12.02%

0

5. Dividend

5.1 Amount

No dividends for NVNO!.
Industry RankSector Rank
Dividend Yield 0%

ENVVENO MEDICAL CORP

NASDAQ:NVNO (1/12/2026, 8:17:05 PM)

After market: 0.3475 +0.01 (+3.42%)

0.336

-0.02 (-6.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-03 2025-11-03/dmh
Earnings (Next)02-26 2026-02-26/amc
Inst Owners20.87%
Inst Owner Change-0.08%
Ins Owners10.76%
Ins Owner Change-2.41%
Market Cap6.79M
Revenue(TTM)N/A
Net Income(TTM)-21.96M
Analysts43.33
Price Target12.75 (3694.64%)
Short Float %13.37%
Short Ratio3.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.65%
Min EPS beat(2)-15.55%
Max EPS beat(2)24.84%
EPS beat(4)3
Avg EPS beat(4)15.45%
Min EPS beat(4)-15.55%
Max EPS beat(4)36.56%
EPS beat(8)6
Avg EPS beat(8)15.09%
EPS beat(12)8
Avg EPS beat(12)8.48%
EPS beat(16)8
Avg EPS beat(16)-14.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.23
EV/EBITDA N/A
EPS(TTM)-1.08
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0
BVpS1.46
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -67.89%
ROE -74.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -8.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.12
Quick Ratio 13.12
Altman-Z -7.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)30.57%
Cap/Depr(5y)103.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.29%
EPS Next Y13.26%
EPS Next 2Y9.4%
EPS Next 3Y12.02%
EPS Next 5Y12.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.93%
OCF growth 3YN/A
OCF growth 5YN/A

ENVVENO MEDICAL CORP / NVNO FAQ

Can you provide the ChartMill fundamental rating for ENVVENO MEDICAL CORP?

ChartMill assigns a fundamental rating of 2 / 10 to NVNO.


What is the valuation status for NVNO stock?

ChartMill assigns a valuation rating of 0 / 10 to ENVVENO MEDICAL CORP (NVNO). This can be considered as Overvalued.


How profitable is ENVVENO MEDICAL CORP (NVNO) stock?

ENVVENO MEDICAL CORP (NVNO) has a profitability rating of 0 / 10.


How financially healthy is ENVVENO MEDICAL CORP?

The financial health rating of ENVVENO MEDICAL CORP (NVNO) is 7 / 10.


What is the earnings growth outlook for ENVVENO MEDICAL CORP?

The Earnings per Share (EPS) of ENVVENO MEDICAL CORP (NVNO) is expected to grow by 13.26% in the next year.